These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21323622)

  • 1. Differential pharmacotherapy for subgroups of fibromyalgia patients with specific consideration of 5-HT3 receptor antagonists.
    Seidel MF; Müller W
    Expert Opin Pharmacother; 2011 Jun; 12(9):1381-91. PubMed ID: 21323622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibromyalgia syndrome: an overview of potential drug targets.
    Briley M; Moret C
    IDrugs; 2003 Jul; 6(7):668-73. PubMed ID: 12861471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibromyalgia syndrome: novel therapeutic targets.
    Ablin JN; Häuser W
    Pain Manag; 2016 May; 6(4):371-81. PubMed ID: 27296699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current experience with 5-HT3 receptor antagonists in fibromyalgia.
    Späth M
    Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Amino-6-chloro-3,4-dihydroquinazoline: A novel 5-HT3 receptor antagonist with antidepressant character.
    Dukat M; Alix K; Worsham J; Khatri S; Schulte MK
    Bioorg Med Chem Lett; 2013 Nov; 23(21):5945-8. PubMed ID: 24035337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT(3) receptors: role in disease and target of drugs.
    Walstab J; Rappold G; Niesler B
    Pharmacol Ther; 2010 Oct; 128(1):146-69. PubMed ID: 20621123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiology and pathophysiology of the 5-HT3 receptor.
    Färber L; Haus U; Späth M; Drechsler S
    Scand J Rheumatol Suppl; 2004; 119():2-8. PubMed ID: 15515404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on pain mechanisms and pharmacotherapy in the treatment of fibromyalgia syndrome.
    Malemud CJ
    Clin Exp Rheumatol; 2009; 27(5 Suppl 56):S86-91. PubMed ID: 20074446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial.
    Crofford LJ; Rowbotham MC; Mease PJ; Russell IJ; Dworkin RH; Corbin AE; Young JP; LaMoreaux LK; Martin SA; Sharma U;
    Arthritis Rheum; 2005 Apr; 52(4):1264-73. PubMed ID: 15818684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose.
    Samborski W; Stratz T; Lacki JK; Klama K; Mennet P; Müller W
    Mater Med Pol; 1996; 28(1):17-9. PubMed ID: 9088121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-depressant-like activity of a novel serotonin type-3 (5-HT3) receptor antagonist in rodent models of depression.
    Gupta D; Devadoss T; Bhatt S; Gautam B; Jindal A; Pandey D; Mahesh R
    Indian J Exp Biol; 2011 Aug; 49(8):619-26. PubMed ID: 21870430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia.
    Vergne-Salle P; Dufauret-Lombard C; Bonnet C; Simon A; Trèves R; Bonnabau H; Bertin P
    Eur J Pain; 2011 May; 15(5):509-14. PubMed ID: 21036635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuronal 5-HT3 receptor network after 20 years of research--evolving concepts in management of pain and inflammation.
    Faerber L; Drechsler S; Ladenburger S; Gschaidmeier H; Fischer W
    Eur J Pharmacol; 2007 Mar; 560(1):1-8. PubMed ID: 17316606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spectrum of use and tolerability of 5-HT3 receptor antagonists.
    Haus U; Späth M; Färber L
    Scand J Rheumatol Suppl; 2004; 119():12-8. PubMed ID: 15515406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant therapy for unexplained symptoms and symptom syndromes.
    O'Malley PG; Jackson JL; Santoro J; Tomkins G; Balden E; Kroenke K
    J Fam Pract; 1999 Dec; 48(12):980-90. PubMed ID: 10628579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
    Seidel MF; Weinreich GF; Stratz T; Müller W
    Rheumatol Int; 2007 Sep; 27(11):1025-30. PubMed ID: 17634903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analgesic effects of 5-HT3 receptor antagonists.
    Riering K; Rewerts C; Zieglgänsberger W
    Scand J Rheumatol Suppl; 2004; 119():19-23. PubMed ID: 15515407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analgesic effects of a 5-HT3 receptor antagonist in an animal model of complex regional pain syndrome.
    Park JH; Lee CH; Ham HD; Choi ES; Lee C; Lee S
    Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7051-7057. PubMed ID: 34859869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pilot study with 5-HT3 antagonists. Good outcome in fibromyalgia pain].
    Stratz T; Müller W
    MMW Fortschr Med; 2002 Mar; 144(11):49. PubMed ID: 12066514
    [No Abstract]   [Full Text] [Related]  

  • 20. Do predictors exist for the therapeutic effect of 5-HT3 receptor antagonists in fibromyalgia?
    Stratz T; Müller W
    Scand J Rheumatol Suppl; 2000; 113():63-5. PubMed ID: 11028835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.